A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Latest Information Update: 23 Jun 2025
At a glance
- Drugs Ponatinib (Primary) ; Cytarabine; Dexamethasone; Imatinib; Methotrexate; Prednisone; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms PhALLCON
- Sponsors Takeda; Takeda Development Center Americas; Takeda Oncology
Most Recent Events
- 01 Jun 2025 Results assessing patient-reported outcomes (PRO) from PhALLCON assessed as exploratory endpoints using the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) and EQ-5D-5L, published in the Leukemia.
- 30 Apr 2025 Results(n=238) evaluating Impact of clinical response and treatment tolerability on HRQoL in patients treated with ponatinib or imatinib presented at the 116th Annual Meeting of the American Association for Cancer Research.
- 25 Nov 2024 According to a Takeda media release, Results from two post-hoc analyses from the Phase 3 PhALLCON trial evaluating ICLUSIG versus imatinib plus reduced-intensity chemotherapy will at the 66th American Society of Hematology (ASH) Annual Meeting being held December 7-10, 2024, in San Diego, California.